Comparing Titan Pharmaceuticals (NASDAQ:TTNP) & TC Biopharm (NASDAQ:TCBP)

Titan Pharmaceuticals (NASDAQ:TTNPGet Free Report) and TC Biopharm (NASDAQ:TCBPGet Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Risk and Volatility

Titan Pharmaceuticals has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500.

Profitability

This table compares Titan Pharmaceuticals and TC Biopharm’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Titan Pharmaceuticals N/A -99.96% -77.58%
TC Biopharm N/A N/A N/A

Valuation & Earnings

This table compares Titan Pharmaceuticals and TC Biopharm’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Titan Pharmaceuticals $180,000.00 26.85 -$5.57 million N/A N/A
TC Biopharm $4.76 million 0.92 -$7.35 million N/A N/A

Titan Pharmaceuticals has higher earnings, but lower revenue than TC Biopharm.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Titan Pharmaceuticals and TC Biopharm, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Titan Pharmaceuticals 0 0 0 0 N/A
TC Biopharm 0 0 0 0 N/A

Institutional & Insider Ownership

31.5% of Titan Pharmaceuticals shares are held by institutional investors. Comparatively, 16.3% of TC Biopharm shares are held by institutional investors. 24.9% of Titan Pharmaceuticals shares are held by insiders. Comparatively, 15.4% of TC Biopharm shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Titan Pharmaceuticals beats TC Biopharm on 5 of the 8 factors compared between the two stocks.

About Titan Pharmaceuticals

(Get Free Report)

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

About TC Biopharm

(Get Free Report)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.